Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Shumak, K. H.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic Purpura

Kenneth H. Shumak; Gail A. Rock; Rama C. Nair, The Canadian Apheresis Group.

15 April 1995 | Volume 122 Issue 8 | Pages 569-572

Objective: To determine the incidence and timing of relapses in patients who have recovered from an acute episode of thrombotic thrombocytopenic purpura.

Design: Clinical follow-up for 3 to 10 years.

Setting: General community outpatient study; patients who had relapse were hospitalized.

Participants: 63 of 72 surviving patients who had participated in a randomized study that compared plasma exchange and plasma infusion as treatments for thrombotic thrombocytopenic purpura and for whom continued clinical follow-up was obtained.

Outcome Measures: Recurrence of thrombotic thrombocytopenic purpura as defined by a decrease in platelet count to less than 100 x 10⁹/L and by the onset of microangiopathic hemolytic anemia as identified by erythrocyte fragmentation in a peripheral blood film.

Results: 37 of the 63 patients have not had recurrence of thrombotic thrombocytopenic purpura and have remained completely well; 6 patients have not had recurrence but have developed other medical problems; 3 patients have not had recurrence but have residual neurologic defects from the original episode; and 17 patients have had one or more recurrences, occurring 7 months to 8 years after the original episode. As determined by Kaplan-Meier analysis, the projected recurrence rate after 10 years in all surviving patients is 36% (95% CI, 23% to 59%).

Conclusions: More than one third of patients who survive an acute episode of thrombotic thrombocytopenic purpura will have at least one relapse during the following 10 years.

Author and Article Information

From the University of Toronto, Toronto, Canada; and the University of Ottawa, Ottawa, Canada.
Requests for Reprints: Kenneth H. Shumak, MD, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, North York, Ontario, Canada M4N 3M5.
Acknowledgments: The authors thank Carole Herbert and Ann Kasaboski for their commitment and for collecting data on patients with thrombotic thrombocytopenic purpura even after the patients were discharged from the hospital.
Grant Support: In part by grant 6613-1158 from the National Health Research and Development Program, Canada, and by the provinces of Canada through the Canadian Blood Agency.

This article has been cited by other articles:

				B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF]

				F. Peyvandi, S. Lavoretano, R. Palla, H. B. Feys, K. Vanhoorelbeke, T. Battaglioli, C. Valsecchi, M. T. Canciani, F. Fabris, S. Zver, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission Haematologica, February 1, 2008; 93(2): 232 - 239. [Abstract] [Full Text] [PDF]

				K. C. Desch and D. G. Motto Thrombotic Thrombocytopenic Purpura in Humans and Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1901 - 1908. [Abstract] [Full Text] [PDF]

				R. M. Perkins, J. C. Reynolds, T. S. Ahuja, T. Reid, L. Y. Agodoa, E. M. Bohen, C. M. Yuan, and K. C. Abbott Thrombotic microangiopathy in United States long-term dialysis patients Nephrol. Dial. Transplant., January 1, 2006; 21(1): 191 - 196. [Abstract] [Full Text] [PDF]

				G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF]

				H.-M. Tsai Platelet Activation and the Formation of the Platelet Plug: Deficiency of ADAMTS13 Causes Thrombotic Thrombocytopenic Purpura Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 388 - 396. [Abstract] [Full Text] [PDF]

				J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF]

				J. Schwartz, A. Eldor, and A. Szold Laparoscopic Splenectomy in Patients With Refractory or Relapsing Thrombotic Thrombocytopenic Purpura Arch Surg, November 1, 2001; 136(11): 1236 - 1238. [Abstract] [Full Text] [PDF]

				J. N. George How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Blood, August 15, 2000; 96(4): 1223 - 1229. [Abstract] [Full Text] [PDF]

				R. E. DREWS and S. E. WEINBERGER Thrombocytopenic Disorders in Critically Ill Patients Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 347 - 351. [Full Text] [PDF]

				S L Allford and S J Machin Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura J. Clin. Pathol., July 1, 2000; 53(7): 497 - 501. [Full Text] [PDF]

				M. Galbusera, M. Noris, C. Rossi, S. Orisio, J. Caprioli, Z. M. Ruggeri, B. Amadei, P. Ruggenenti, B. Vasile, G. Casari, et al. Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families Blood, July 15, 1999; 94(2): 610 - 620. [Abstract] [Full Text] [PDF]

				D. K. Chen, J. S. Kim, and D. M. C. Sutton Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use: A Report of 3 Cases and Review of the Literature Arch Intern Med, February 8, 1999; 159(3): 311 - 314. [Abstract] [Full Text] [PDF]

				A. A. Pineda and E. C. Vamvakas Applications of Therapeutic Apheresis in Patients with Malignant Disease Oncologist, April 1, 1997; 2(2): 94 - 103. [Abstract] [Full Text] [PDF]